Download MendeleyNovel sialic acid derivatives lock open the 150-loop of an influenza A virus group-1 sialidase.
Rudrawar, S., Dyason, J.C., Rameix-Welti, M.A., Rose, F.J., Kerry, P.S., Russell, R.J., van der Werf, S., Thomson, R.J., Naffakh, N., von Itzstein, M.(2010) Nat Commun 1: 113-113
- PubMed: 21081911
- DOI: https://doi.org/10.1038/ncomms1114
- Primary Citation of Related Structures:
3O9J, 3O9K - PubMed Abstract:
Influenza virus sialidase has an essential role in the virus' life cycle. Two distinct groups of influenza A virus sialidases have been established, that differ in the flexibility of the '150-loop', providing a more open active site in the apo form of the group-1 compared to group-2 enzymes. In this study we show, through a multidisciplinary approach, that novel sialic acid-based derivatives can exploit this structural difference and selectively inhibit the activity of group-1 sialidases. We also demonstrate that group-1 sialidases from drug-resistant mutant influenza viruses are sensitive to these designed compounds. Moreover, we have determined, by protein X-ray crystallography, that these inhibitors lock open the group-1 sialidase flexible 150-loop, in agreement with our molecular modelling prediction. This is the first direct proof that compounds may be developed to selectively target the pandemic A/H1N1, avian A/H5N1 and other group-1 sialidase-containing viruses, based on an open 150-loop conformation of the enzyme.
Organizational Affiliation:
Institute for Glycomics, Gold Coast Campus, Griffith University, Queensland 4222, Australia.
